NewsSource: EClinCloud

Stay Away from Depression — Check Out the Depression Self-Rating Scale

8 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

[Introduction]

Recently, renowned singer Coco Lee tragically passed away due to depression. When the news broke, it caused widespread shock. Amid the shock and grief, people have also begun paying closer attention to mental health. Anyone can face the risk of depression. So, what is depression, and how can you tell if you have it?

Article illustration

01

What We Should Know About Depression

Depressive disorder refers to a group of mood disorders caused by various factors and characterized primarily by marked and persistent depressed mood[1].

Major depressive disorder (MDD) is the most common type of depressive disorder[1]. As a chronic, recurrent illness, its symptoms—such as depressed mood, slowed thinking, fatigue, and lethargy—severely impair patients' academic, daily, and social functioning[2]; meanwhile, its high incidence, high recurrence rate, and high suicide rate also place a heavy burden on patients and public healthcare services.

If you experience depressed mood in daily life, such as:

  • Feelings of inferiority, self-blame, depressed mood, or pessimism

  • Loss of confidence in the future of your work, studies, or life

  • Loss of interest and loss of pleasure

  • Even feeling that life is worse than death and each day drags on like a year

  • Thoughts of self-harm or suicidal attempts and behaviors

and on top of that, accompanied by 4 or 4+ of the following symptoms—such as changes in appetite or weight, hypersomnia or insomnia, fatigue and weakness, slowed movement, slowed thinking, difficulty concentrating, restlessness, or anxiety—lasting 2 or 2+ weeks, depression may be considered, and psychological testing using a depression scale is even more helpful for diagnosis[3].

02

Are There Medications to Treat Depression?

Article illustration

Marketed Drugs for Depression

Currently, commonly used clinical medications for MDD include:

  • Selective 5-HT (serotonin) reuptake inhibitors (SSRIs, such as escitalopram, sertraline, and fluoxetine)

  • 5-HT (serotonin) and norepinephrine reuptake inhibitors (SNRIs, such as venlafaxine and duloxetine)

  • Noradrenergic and specific 5-HT (serotonergic) antidepressants (NaSSAs, such as mirtazapine)

  • Tricyclic and tetracyclic antidepressants

  • Monoamine oxidase inhibitors (MAOIs)

Among these, SSRIs and SNRIs are currently the mainstay drugs for MDD, yet most have drawbacks such as slow onset of action, limited response rates, and causing sexual dysfunction and cognitive impairment. In addition, traditional Chinese medicines for MDD have also been approved and marketed in China in recent years, mainly including Yiling Pharmaceutical's Jieyu Chufan Capsules, Kanghong Pharmaceutical's Shugan Jieyu Capsules, and Zuoli Pharmaceutical's Wuling Capsules, among others.

Investigational Drugs for Depression

Despite advances in MDD research and pharmaceutical technology, many unmet clinical needs remain in this field, and safer, more effective drugs are urgently needed. Based on a search of recent clinical trial programs, information on selected investigational drugs is summarized below:
Article illustration

Note: In February 2023, the FDA accepted the marketing application for zuranolone for the treatment of severe MDD and postpartum MDD and granted it Priority Review, with a PDUFA date of August 5, 2023.

03

How Can You Tell If You Have Depression?

The most widely used depression assessment tool in clinical research is the Montgomery-Asberg Depression Rating Scale (MADRS). Other commonly used depression scales include the Hamilton Depression Rating Scale (HAMD) and the 9-item Patient Health Questionnaire (PHQ-9). We have compiled relevant information on these commonly used depression scales below for a closer look.

Montgomery-Asberg Depression Rating Scale (MADRS)

The MADRS is a depression subscale developed by Montgomery SA and Asberg M in 1979 from the Comprehensive Psychopathological Rating Scale (CPRS), with the aim of reorganizing a scale sensitive to changes in depressive symptoms, particularly the effects of antidepressant treatment. The MADRS consists of the 10 most common and sensitive depressive symptoms from the CPRS, uses a 7-point rating scale from 0 to 6, and is widely used in pharmaceutical research in the mental health field.

Article illustration

The scale should be administered by experienced specialist practitioners as raters; except for item 1, which is an observation item, all remaining items are rated based on the subject's self-report. The assessment uses an open-ended format similar to a general clinical interview and takes 15 minutes per assessment. The total MADRS score ranges from 0 to 60. Generally, a score of 0–11 is considered to indicate no clinically significant depressive symptoms, 12–23 mild depression, 24–34 moderate depression, and >35 severe depression. The scale demonstrates good reliability and validity, with inter-rater reliability R = 0.89–0.95.

Hamilton Depression Rating Scale (HAMD)

Developed by Hamilton in 1960, the HAMD is the most commonly used scale in clinical practice for assessing depressive states. The scale has multiple versions, with 3 commonly used versions: 17-item, 21-item, and 24-item. Most HAMD items use a 5-point rating scale from 0 to 4 [0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe]; a few items use a 3-point rating scale from 0 to 2 [0 = absent, 1 = mild to moderate, 2 = severe]. The 21-item version has 3 fewer items than the 24-item scale (items 22, 23, and 24), and the most commonly used version is the 17-item version, which omits items 18–24.
Article illustration
This scale is suitable for adult patients with depressive symptoms; patients should be evaluated by a trained rater, generally through interview and observation. The assessment timeframe is generally the past 1 week, though it may also be specified otherwise as needed. A single assessment takes 15–20 minutes. On the 24-item HAMD, a total score above 35 may indicate severe depression; a score above 20 may indicate mild or moderate depression; and a score below 8 indicates no depressive symptoms. The corresponding cutoff scores for HAMD-17 are 24, 17, and 7. The inter-rater reliability of this scale is also strong, with a reliability coefficient R of 0.88–0.99 for the total score, and it reflects disease severity well.

9-Item Patient Health Questionnaire (PHQ-9)

The PHQ-9 is derived from the depression module of the Patient Health Questionnaire (PHQ) developed by Spitzer et al. (1999), also known as the Patient Health Questionnaire Depression Scale; it is widely recommended for its ease of use. The scale comprises 10 items in total, including a 9-item symptom scale and 1 overall functional assessment item. The symptom scale assesses: (1) diminished interest, (2) depressed mood, (3) sleep disturbances, (4) fatigue, (5) eating disturbances, (6) feelings of inferiority, (7) difficulty concentrating, (8) psychomotor retardation, and (9) suicidal symptoms; item 10 is an overall functional assessment. It uses a 4-point scoring system from 0 to 3, rated according to the frequency of symptoms over the past 2 weeks.

Article illustration
This scale is self-rated. Before testing, ensure that the subject understands the purpose and method of the assessment; then ask the subject to read each item carefully and complete it independently once understood.
The total PHQ score is the sum of items 1 to 9, ranging from 0 to 27; the score can be used to assess the severity of depressive symptoms:
  • 0–4 points: no depressive symptoms

  • 5–9 points: mild

  • 10–14 points: moderate

  • 15 points and above: severe

The PHQ-9 demonstrates good reliability and validity, with an internal consistency α of 0.86–0.89 and test-retest reliability of 0.83–0.84; its sensitivity and specificity for diagnosing depression are 0.77–0.88 and 0.92–0.94, respectively. You can also use the PHQ-9 scale shown in the figure above to check whether you may have depressive tendencies.
Article illustration

Depression is nothing to fear—face it squarely, understand it, and treat people living with depression with kindness. If you have friends or family members around you who have been diagnosed with depression or show depressive tendencies, we hope that by learning about depression, you can help them seek formal treatment and support them out of the darkness with greater kindness and care. Believe that one day you can make peace with it.


References

[1] Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, et al. Guideline for Primary Care of Depressive Disorder (2021) (抑郁症基层诊疗指南(2021年)). Chinese Journal of General Practitioners, 2021, 20(12): 1249-1260.

[2] Luo Yang, Shi Jing, Zhang Mingxia, Ding Zhuolei, Liu Sijia, Zan Siyan, Du Ruonan, Tan Yunlong, Yang Fude, Wang Zhiren. Characteristics of Intrinsic Motivation in Patients with Depression (抑郁症患者的内在动机特征). Chinese Mental Health Journal, 2023,37(4): 279-285.

[3] Ding Qinzhang. Treatment Guidelines for Depression (抑郁症的治疗指南). Chinese Journal for Clinicians, 2002,30(3): 21-22.

[4] Zhang Mingyuan, He Yanling. Handbook of Psychiatric Rating Scales (精神科评定量表手册). Hunan Science and Technology Press, 2015.




About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interoperable all-in-one clinical trial cloud platform (including solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis across technology products and offerings including eCOA, CTMS, eTMF, EDC, RTSM, and RM) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining cutting-edge technology with life data to build a globally leading "patient-centric" clinical evidence support SaaS cloud platform, it helps domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.